KaloBios CEO to Participate at FDA/CMS Summit

BRISBANE, Calif., Dec. 13, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. KBIO, a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will discuss how Priority Review Vouchers (PRVs) can continue to be effective incentives to help underserved patients during a panel at the U.S. Food and Drug Administration (FDA) / Centers for Medicare and Medicaid Services (CMS) Summit in Washington, D.C., December 14-15, 2016.

Dr. Durrant will also participate in a separate discussion on the significant needs in pediatric drug development.

"Important incentives, such as the PRV system, can support new approaches to bring treatments to many categories of underserved patients, including children," said Dr. Durrant. "I look forward to engaging regulatory, policy and other stakeholders on how we could further collaborate and share ideas to help overlooked populations."

Details of the panels follow:

Title: Priority Review Voucher Proliferation: Bane of FDA, Boon for Industry?
Date: Wednesday, December 14, 2016
Time: 3:30 – 4:00 p.m. EST
Participants: Krista Carver, Covington & Burling LLP; Dr. Gayatri Rao, Office of Orphan Products Development, FDA; Dr. Cameron Durrant, KaloBios Pharmaceuticals

Title: Pediatric Drug Development
Date: Thursday, December 15, 2016
Time: 11:15 a.m. – 12:00 p.m. EST
Participants: Dr. Mary Dianne Murphy, Office of Pediatric Therapeutics, FDA (retired); Dr. Stephen Yoo, REGENXBIO; Dr. Cameron Durrant, KaloBios Pharmaceuticals

For more information on the conference, please visit https://lifesciences.knect365.com/fda-cms/.

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. KBIO is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.